论文部分内容阅读
肿瘤多药耐药是本期文章收录的主题.肿瘤多药耐药(multidrug resistance,MDK)是指肿瘤细胞在对一种抗肿瘤药物出现耐受(抵抗)的同时,对其他多种结构各异、作用机制不同的抗癌药物产生交义耐药的现象。MUK是当前肿瘤治疗中最常见和最棘手的问题,其产生机制非常复杂,包括细胞膜蛋白质异常改变,如P-糖蛋白(P-gP)、多药耐药相关蛋白(MRP)等过度表达;细胞内酶异常改变,如谷胱甘肽S转移酶(GST)活性增
Multidrug resistance (MDR) is the subject of this issue.Multidrug resistance (MDR) refers to the ability of tumor cells to tolerate (resist) an anti-tumor drug, Different, different mechanisms of action of anti-cancer drugs have a cross-resistant phenomenon. Currently, MUK is the most common and intractable problem in oncology treatment. Its mechanism of production is very complex, including abnormal changes of cell membrane proteins such as P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP) Abnormal changes in intracellular enzymes, such as glutathione S transferase (GST) activity increased